CONTROLLING HIV/SIV WITH DRUGS THAT MANIPULATE LYMPHOCYTE TRAFFICKING

$56,690P51FY2009RRNIH

Emory University, Atlanta GA

Investigators

Linked publications & trials

Paper 38214558 Paper 37693595 Paper 36114169 Paper 36074577 Paper 35445423 Paper 34855621 Paper 34498433 Paper 34437736 Paper 33910220 Paper 33707771 Paper 33529681 Paper 33463551 Paper 33359631 Paper 33338613 Paper 33137689 Paper 33084571 Paper 32951543 Paper 32905842 Paper 32612608 Paper 32580662 Paper 32569766 Paper 32561559 Paper 32332110 Paper 32250460 Paper 31926168 Paper 31904583 Paper 31898839 Paper 31722194 Paper 31643109 Paper 31455727 Paper 31341049 Paper 31080066 Paper 30910223 Paper 30807811 Paper 30778066 Paper 30718403 Paper 30541829 Paper 30502901 Paper 30486918 Paper 30450384 Paper 30295946 Paper 30237074 Paper 30232277 Paper 30178424 Paper 30021123 Paper 29997216 Paper 29987877 Paper 29983703 Paper 29978933 Paper 29929489 Paper 29928280 Paper 29887142 Paper 29777188 Paper 29752749 Paper 29657070 Paper 29614657 Paper 29510099 Paper 29508924 Paper 29454797 Paper 29386136 Paper 29357021 Paper 29345365 Paper 29158413 Paper 29133346 Paper 29065175 Paper 28926189 Paper 28899729 Paper 28862836 Paper 28842187 Paper 28829774 Paper 28819207 Paper 28648500 Paper 28622613 Paper 28483344 Paper 28483199 Paper 28461219 Paper 28377304 Paper 28369850 Paper 28337120 Paper 28289708 Paper 28269776 Paper 28242325 Paper 28215744 Paper 28159893 Paper 28126752 Paper 28093566 Paper 28051083 Paper 28030956 Paper 28027448 Paper 28025095 Paper 27942478 Paper 27931313 Paper 27928002 Paper 27893962 Paper 27880897 Paper 27870344 Paper 27870343 Paper 27861291 Paper 27851926 Paper 27849172

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Building upon surprising results obtained in our laboratory in the mouse/LCMV model, this project is designed to test the ability of FTY720[unreadable]a drug that blocks exit of lymphocytes from lymph nodes and that has been through phase II clinical trials for treating multiple sclerosis and preventing kidney transplant rejection[unreadable]to enhance the immunological control of SIV in chronically infected rhesus macaques. We had discovered a completely novel and surprising immunotherapy that leads to complete clearance of an otherwise chronic infection of LCMV in the mouse. For a one year pilot project in the SIV/NHP model, we will focus on one of two treatment modes: (1) immediate post-exposure treatment, or (2) treatment of an established of chronic infection. We will choose the latter because of (1) its greater potential impact (in the context of treating HIV), and (2) it is likely to produce data that is more interpretable because we will be able to determine drug-associated changes in viral load relative to known set points (allowing us to use fewer animals). There are three possible results for these experiments: (1) no change in viral load;(2) a drug associated increase in viral load, possibly due to concentrating target cells for infection (CD4+) in lymph nodes;or (3) a drug associated decrease in viral load, as in the LCMV model. If the latter is observed, human clinical trials may be warranted, and it helps that FTY720 has been extensively tested in human clinical trials for treatment of MS and solid organ transplantation.

View original record on NIH RePORTER →